+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Nitric oxide reverts the resistance to doxorubicin in human colon cancer cells by inhibiting the drug efflux



Nitric oxide reverts the resistance to doxorubicin in human colon cancer cells by inhibiting the drug efflux



Cancer Research 65(2): 516-525



Multidrug resistance (MDR) is a phenomenon by which cancer cells evade the cytotoxic effects of chemotherapeutic agents. It may occur through different mechanisms, but it often correlates with the overexpression of integral membrane transporters, such as P-glycoprotein (Pgp) and MDR-associated proteins (MRPs), with resulting decrease of drug accumulation and cellular death.

(PDF emailed within 1 workday: $29.90)

Accession: 012356546

Download citation: RISBibTeXText

PMID: 15695394


Related references

RhoA silencing reverts the resistance to doxorubicin in human colon cancer cells. Molecular Cancer Research 6(10): 1607-1620, 2008

Nitric oxide donor doxorubicins accumulate into Doxorubicin-resistant human colon cancer cells inducing cytotoxicity. Acs Medicinal Chemistry Letters 2(7): 494-497, 2011

Liposome-encapsulated doxorubicin reverses drug resistance by inhibiting P-glycoprotein in human cancer cells. Molecular Pharmaceutics 8(3): 683-700, 2011

Isocyclopamine, a novel synthetic derivative of cyclopamine, reverts doxorubicin resistance in MCF-7/ADR cells by increasing intracellular doxorubicin accumulation and downregulating breast cancer stem-like cells. Tumour Biology 37(2): 1919-1931, 2015

Treatment of human breast cancer cells with nitric oxide mimetics prevents acquisition of hypoxia-induced resistance to doxorubicin. Proceedings of the American Association for Cancer Research Annual Meeting 42: 814-815, March, 2001

Differential effects of doxorubicin and docetaxel on nitric oxide production and inducible nitric oxide synthase expression in MCF-7 human breast cancer cells. Oncology Research 14(7-8): 381-386, 2004

Targeted delivery of doxorubicin through conjugation with EGF receptor-binding peptide overcomes drug resistance in human colon cancer cells. British Journal of Pharmacology 168(7): 1719-1735, 2013

Mad1 mediates hypoxia-induced doxorubicin resistance in colon cancer cells by inhibiting mitochondrial function. Free Radical Biology & Medicine 60: 201-210, 2013

Treatment of doxorubicin-resistant MCF7/Dx cells with nitric oxide causes histone glutathionylation and reversal of drug resistance. Biochemical Journal 440(2): 175-183, 2012

Antioxidant rich Morus alba leaf extract induces apoptosis in human colon and breast cancer cells by the downregulation of nitric oxide produced by inducible nitric oxide synthase. Nutrition and Cancer 65(2): 305-310, 2013

Effects of nitric oxide on red blood cells: Changes in erythrocyte resistance to hypotonic hemolysis and potassium efflux by experimental maneuvers that decrease nitric oxide. Biochemical and Biophysical Research Communications 199(2): 447-454, 1994

Quantitation of doxorubicin uptake, efflux, and modulation of multidrug resistance (MDR) in MDR human cancer cells. Journal of Pharmacology and Experimental Therapeutics 324(1): 95-102, 2007

Alpha-tocopheryl succinate enhances doxorubicin-induced apoptosis in human gastric cancer cells via promotion of doxorubicin influx and suppression of doxorubicin efflux. Cancer Letters 307(2): 174-181, 2011

Nitric oxide attenuates resistance to doxorubicin in three-dimensional aggregates of human breast carcinoma cells. Breast Cancer Research and Treatment 96(2): 169-176, 2005

Nitric oxide releasing acridone carboxamide derivatives as reverters of doxorubicin resistance in MCF7/Dx cancer cells. Bioorganic Chemistry 64: 51-58, 2015